On April 4, 2023, the Department of Science and Technology of Henan Province led an expert review team to Henan Zhimei Pharmaceutical Co., Ltd. to conduct final acceptance of the company's major scientific and technological project "Research and Development of BTK Inhibitors as a New Drug" in Henan Province.

　　The acceptance team experts conducted a professional and rigorous review, verifying each item against the project performance target requirements. The project under review is the research and development of a new class of BTK inhibitors. The project was launched in November 2020. Under the influence of the COVID-19, the researchers of EMICRO Biomedicines have made great efforts to complete the design, synthesis and bioactivity screening of the target compounds, research on the process of APIs and preparations, as well as amplification, research on the methodology of the quality standards of APIs and preparations, and non clinical research, including pharmacokinetics, pharmacodynamics, safety evaluation, etc. Due to its standardized project management and achievement of performance targets, after strict and meticulous verification and review by the expert group, it is believed that the project research meets the performance target requirements. After passing the acceptance, the company will also receive a large amount of scientific research funding support.